Clinical Rheumatology

, Volume 33, Issue 1, pp 137–139

Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases

  • C. Sengler
  • M. Niewerth
  • T. Kallinich
  • A. Nimtz-Talaska
  • M. Haller
  • H.-I. Huppertz
  • K. Minden
Brief Report

DOI: 10.1007/s10067-013-2435-8

Cite this article as:
Sengler, C., Niewerth, M., Kallinich, T. et al. Clin Rheumatol (2014) 33: 137. doi:10.1007/s10067-013-2435-8
  • 123 Downloads

Abstract

The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented—38 % under treatment with biologicals—of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.

Keywords

ChildrenDisease activityFlareH1N1 influenza vaccinationRheumatic disease

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • C. Sengler
    • 1
  • M. Niewerth
    • 1
  • T. Kallinich
    • 2
  • A. Nimtz-Talaska
    • 3
  • M. Haller
    • 4
  • H.-I. Huppertz
    • 5
  • K. Minden
    • 1
  1. 1.Epidemiology UnitGerman Rheumatism Research Centre Berlin, Leibniz InstituteBerlinGermany
  2. 2.Children’s University Hospital, Department of Pediatric Pneumology and ImmunologyCharité—Universitätsmedizin BerlinBerlinGermany
  3. 3.Pediatrician/Pediatric Rheumatologist in Private PracticeFrankfurt/OderGermany
  4. 4.Pediatrician/Pediatric Rheumatologist in Private PracticeGundelfingenGermany
  5. 5.Klinikum Bremen MitteBremenGermany